STAAR Surgical (STAA) Projected to Post Earnings on Wednesday

Key Points

• STAAR Surgical is expected to release its Q3 2025 earnings on October 29, 2025, with analysts predicting earnings of $0.18 per share and revenue of $92.153 million.
• The company's stock opened at $26.69, and it has shown a one-year high of $32.00 and a low of $13.50, with a current market cap of $1.32 billion.
• Recent analyst ratings indicate that ten analysts have rated STAAR Surgical as a Hold, with a consensus price target of $20.67.

STAAR Surgical (NASDAQ:STAA - Get Free Report) is anticipated to post its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect STAAR Surgical to post earnings of $0.18 per share and revenue of $92.1530 million for the quarter. Parties can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

STAAR Surgical Price Performance

NASDAQ STAA opened at $26.69 on Wednesday. The stock's 50 day simple moving average is $27.18 and its 200 day simple moving average is $21.35. STAAR Surgical has a one year low of $13.50 and a one year high of $32.00. The firm has a market cap of $1.32 billion, a PE ratio of -13.83 and a beta of 0.82.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently bought and sold shares of STAA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in STAAR Surgical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier's stock worth $518,000 after acquiring an additional 1,267 shares in the last quarter. Goldman Sachs Group Inc. increased its position in STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier's stock worth $9,606,000 after buying an additional 136,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in STAAR Surgical by 11.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier's stock valued at $2,175,000 after buying an additional 12,841 shares during the period. Creative Planning raised its stake in STAAR Surgical by 19.9% in the second quarter. Creative Planning now owns 15,695 shares of the medical instruments supplier's stock valued at $263,000 after buying an additional 2,606 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of STAAR Surgical by 183.2% in the second quarter. JPMorgan Chase & Co. now owns 153,371 shares of the medical instruments supplier's stock valued at $2,574,000 after buying an additional 99,218 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on STAA shares. Mizuho lifted their price target on shares of STAAR Surgical from $17.00 to $18.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 16th. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $28.00 price objective on shares of STAAR Surgical in a research note on Tuesday. Stifel Nicolaus set a $28.00 target price on shares of STAAR Surgical and gave the stock a "hold" rating in a report on Thursday, August 7th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of STAAR Surgical in a research report on Wednesday, October 8th. Ten analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Reduce" and a consensus price target of $20.67.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.